DEZHAN HEALTHCARE(SZ:000813)2024-04-11 16:00Company Overview - Dezhang Health reported no cash dividends, stock bonuses, or capital increases from reserves for the year 2023[3]. - The company underwent a significant business transformation in 2016, shifting from textile and mining industries to fully focus on the pharmaceutical sector by acquiring 100% equity of Jialin Pharmaceutical[18]. - The company’s stock is listed on the Shenzhen Stock Exchange under the code 000813[15]. - The registered address of Dezhang Health is located at Financial Building, No. 53 Jinyin Road, Tianshan District, Urumqi, Xinjiang, with a postal code of 830002[15]. - The company has a dual headquarters in Beijing and Urumqi, with the office in Beijing located at Bona Building, No. 2 Gongti East Road, Chaoyang District[15]. - The company’s website is www.dezhanhealthcare.com, providing access to financial reports and other investor information[15]. - The company’s legal representative is Wei Zheming, who is also responsible for the financial reporting accuracy[2]. Financial Performance - The company's operating revenue for 2023 was ¥498,088,171.28, a decrease of 12.75% compared to ¥570,855,435.18 in 2022[20]. - The net profit attributable to shareholders for 2023 was ¥83,314,246.81, representing a significant increase of 277.45% from a loss of ¥46,908,665 in 2022[20]. - The net cash flow from operating activities decreased by 20.93% to ¥127,872,780.78 in 2023, down from ¥161,719,681 in 2022[20]. - The total assets at the end of 2023 were ¥5,378,612,557.62, reflecting a decline of 5.24% from ¥5,674,395,997.63 at the end of 2022[21]. - The net assets attributable to shareholders decreased by 1.03% to ¥5,237,902,679.94 at the end of 2023, compared to ¥5,292,645,218.23 at the end of 2022[21]. - The basic earnings per share for 2023 was ¥0.0382, a turnaround from a loss of ¥0.0212 in 2022, marking an increase of 280.19%[20]. - The company reported a total of ¥150,080,266.75 in non-recurring gains for 2023, compared to ¥34,291,294.26 in 2022[26]. Market and Product Insights - The market size of lipid-regulating agents in China was approximately 22.5 billion yuan in 2022, with sales in public medical institutions exceeding 16.6 billion yuan, a year-on-year increase of 12.53%[31]. - Atorvastatin calcium tablets generated sales of 4.428 billion yuan in 2022, with a year-on-year growth of 7.45%[35]. - The sales of amlodipine atorvastatin calcium tablets increased by 18.42% in the first half of 2022[36]. - The company’s core products include atorvastatin calcium tablets and amlodipine atorvastatin calcium tablets, which are positioned as market leaders in their categories[37]. - The company has been deeply rooted in the Chinese lipid-lowering drug market for 20 years, successfully establishing the "Aler Quality" concept with its main product, Aler, which is the first generic version of the globally top-selling prescription drug Lipitor in China[51]. Research and Development - The company has established a technology R&D platform with approximately 200 high-educated professionals, accounting for about 20% of total employees, focusing on technology improvement and new drug development[52]. - The company is focusing on innovation in drug development, with resources being directed towards promising areas such as WYY and semaglutide[55]. - The company is advancing its innovative drug projects, including a neuroprotective agent for acute ischemic stroke, with key initial material trials underway[76]. - The company is expanding its product offerings with new biopharmaceuticals, including semaglutide for type II diabetes and collagen products for post-surgical recovery[77]. Strategic Initiatives - The company is actively exploring new business areas, including biopolypeptides and medical services, with products already launched in these segments[37]. - The company aims to reduce the premature mortality rate from cardiovascular diseases by 20% by 2025, as outlined in the national chronic disease prevention plan[45]. - The company has implemented strategies to enhance brand value and customer loyalty through training and promotional activities in collaboration with major retail chains[46]. - The company plans to enhance its market position by focusing on new product development and strategic acquisitions in the healthcare sector[112]. Governance and Management - The company has established a governance structure consisting of a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective operation and decision-making[129]. - The board of directors comprises 9 members, including 3 independent directors, and has established specialized committees to enhance governance and oversight[130]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, organization, and finance, ensuring independent accounting and risk management[133]. - The company has a complete set of management systems covering financial, production, and sales processes, continuously improving according to legal requirements[131]. Sustainability and Corporate Responsibility - The management emphasized a commitment to sustainability, planning to invest 100 million RMB in eco-friendly initiatives over the next three years[147]. - The company is committed to enhancing investor protection through rigorous audit processes and compliance measures[165]. - The company has not faced any significant environmental protection issues as a key pollutant discharge unit[194]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 1,002, with 972 from major subsidiaries and 30 from the parent company[169]. - The company has implemented a salary policy based on "position determines salary, salary changes with position changes, and performance-based compensation"[170]. - A total of 24 training programs were conducted in 2023, covering various topics including GMP regulations, financial management, and safety training[171]. Future Outlook - Future performance guidance remains optimistic, with expectations for continued growth in revenue and market share[138]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[147]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 500 million RMB allocated for this purpose[147].